
- /
- Supported exchanges
- / MU
- / HDP1.MU
ARROWHEAD RESEARCH (HDP1 MU) stock market data APIs
ARROWHEAD RESEARCH Financial Data Overview
There is no Profile data available for HDP1.MU.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ARROWHEAD RESEARCH data using free add-ons & libraries
Get ARROWHEAD RESEARCH Fundamental Data
ARROWHEAD RESEARCH Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARROWHEAD RESEARCH News

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
- Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias - YOSEMITE Phase 3 study further enhances Arrowhead’s late-stage pipeline of RNAi-based cardiometab...


Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
Company Logo The global chronic hepatitis B market is experiencing growth due to breakthroughs in diagnosis and treatment, including gene-editing and immune modulation therapies. With therapies advan...

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
- Study completion anticipated in mid-2026 with subsequent data readout and regulatory submissions for treatment of severe hypertriglyceridemia PASADENA, Calif., June 23, 2025--(BUSINESS WIRE)--Arrow...

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”
We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other sto...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.